Anti-SUPT20H monoclonal antibody

Pre-made anti-SUPT20H monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SUPT20H/SUPT20H products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2914-Ab-1/ GM-Tg-hg-IP2914-Ab-2Anti-Human SUPT20H monoclonal antibodyHuman
GM-Tg-rg-IP2914-Ab-1/ GM-Tg-rg-IP2914-Ab-2Anti-Rat SUPT20H monoclonal antibodyRat
GM-Tg-mg-IP2914-Ab-1/ GM-Tg-mg-IP2914-Ab-2Anti-Mouse SUPT20H monoclonal antibodyMouse
GM-Tg-cynog-IP2914-Ab-1/ GM-Tg-cynog-IP2914-Ab-2Anti-Cynomolgus/ Rhesus macaque SUPT20H monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2914-Ab-1/ GM-Tg-felg-IP2914-Ab-2Anti-Feline SUPT20H monoclonal antibodyFeline
GM-Tg-cang-IP2914-Ab-1/ GM-Tg-cang-IP2914-Ab-2Anti-Canine SUPT20H monoclonal antibodyCanine
GM-Tg-bovg-IP2914-Ab-1/ GM-Tg-bovg-IP2914-Ab-2Anti-Bovine SUPT20H monoclonal antibodyBovine
GM-Tg-equg-IP2914-Ab-1/ GM-Tg-equg-IP2914-Ab-2Anti-Equine SUPT20H monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2914-Ab-1/ GM-Tg-hg-IP2914-Ab-2; GM-Tg-rg-IP2914-Ab-1/ GM-Tg-rg-IP2914-Ab-2;
GM-Tg-mg-IP2914-Ab-1/ GM-Tg-mg-IP2914-Ab-2; GM-Tg-cynog-IP2914-Ab-1/ GM-Tg-cynog-IP2914-Ab-2;
GM-Tg-felg-IP2914-Ab-1/ GM-Tg-felg-IP2914-Ab-2; GM-Tg-cang-IP2914-Ab-1/ GM-Tg-cang-IP2914-Ab-2;
GM-Tg-bovg-IP2914-Ab-1/ GM-Tg-bovg-IP2914-Ab-2; GM-Tg-equg-IP2914-Ab-1/ GM-Tg-equg-IP2914-Ab-2
Products NameAnti-SUPT20H monoclonal antibody
Formatmab
Target NameSUPT20H
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SUPT20H monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2914-Ag-1Recombinant multi-species SP20H/ SUPT20H/ C13 protein


    Target information

    Target IDGM-IP2914
    Target NameSUPT20H
    Gene ID55578,56790,361946,696174,477299,101086619,534126,100062531
    Gene Symbol and SynonymsC13,C13orf19,D3Ertd300e,FAM48A,FP757,P38IP,RGD1307812,SPT20,Supt20,SUPT20H
    Uniprot AccessionQ8NEM7,Q66HC7
    Uniprot Entry NameSP20H_HUMAN,SP20H_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000102710
    Target ClassificationN/A

    The target: SUPT20H, gene name: SUPT20H, also named as C13, C13orf19, FAM48A, FP757, P38IP, SPT20. Predicted to enable transcription coregulator activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to act upstream of or within positive regulation of gluconeogenesis and positive regulation of transcription by RNA polymerase II. Part of SAGA-type complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.